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Antimicrobial Peptides in Healthy
Skin and Atopic Dermatitis
Jens-M. Schröder1
ABSTRACT
Antimicrobial Peptides and Proteins (AMPs) represent effector molecules of the innate defense system in all or-
ganisms. AMPs are either constitutively or inducibly produced mainly by various epithelial cells, including
keratinocytes. This report reviews our current knowledge about the major yet known keratinocyte-derived
AMPs, its role in healthy skin and atopic dermatitis.
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INTRODUCTION
All multicellular organisms, including plants, inverte-
brates, vertebrates and humans, are in contact with
potentially pathogenic microbes and are covered with
an organism- and location-specific microflora, but are
rarely infected. The human body contains nearly 1014
cells, of which only 10% are body cells; the remaining
are microbes within the body (mainly in the gut) and
at epithelial surfaces such as the skin and the upper
aero-digestive tract as well as the genito-urinary tract.
Thus it is really surprising that these microbes do not
infect the organisms, although there are several loca-
tions which might represent ideal habitats for mi-
crobes (such as the mouth, the genito-urinary tract,
the gut and axillae) due to the presence of humidity,
nutrients and electrolytes.
Effector cells of our immune system cannot explain
this surprising fact because the by far majority of
multicellular organism lack an immune system.
Therefore it is tempting to speculate that there exists
a very efficient, ancient defense system at body sur-
faces which protects the organisms from infection.
INNATE EPITHELIAL DEFENSE MECHA-
NISMS IN PLANTS AND INVERTEBRATES
The roots of germinating plant seed are in contact
with numerous soil bacteria and fungi, but remain un-
infected. This is achieved by epithelial production
and release of antimicrobial components, mainly pep-
tides.1 These are mainly located within the upper-
most epidermal cell layers of different plant organs.2
Similarly invertebrates such as insects have a very
effective epithelial defense system: Upon microbial
challenge e.g. the fruit fly Drosophila melanogaster
produces in a microbe-selective manner epithelial
AMPs, which are highly active against the challeng-
ing microbe.3
Unlike insects, which also contain a phagocyte-
based defense system, the sweet water polyp Hydra
vulgaris solely contains epithelial cells to defend in-
fection.4 Indeed, the outer epithelia produce a num-
ber of AMPs, which at least in part are induced upon
challenge of these animals with microbial products
via a two-component “Toll-like-receptor-like Recep-
tor”.5 This animal is living in ponds, being exposed to
huge numbers of microbes such as Pseudomonas spe-
cies, but not infected!
EPITHELIAL DEFENSE IN VERTEBRATES
The first evidence that also vertebrates possess an
epithelial defense system comes from the observation
that freshly operated frogs, which have been taken
into a pond, usually did not develop wound infec-
tions.6 It was hypothesized that antimicrobial compo-
nents, secreted from frog skin, protect wounds from
infection. A subsequent analysis led to the discovery
of the AMP Magainin.
Also mammalian epithelia are normally free of in-
fection. In cattle a number of epithelia-derived AMPs
called β-defensins have been identified, which show a
more or less epithelia-specific expression pattern.7
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Most of these β-defensins are absent in healthy epi-
thelia and are inducible upon contact with microbes.7
Apart from β-defensins, gut epithelia of mice are capa-
ble to produce structurally related α-defensins like
the cryptdins8 and cryptdin-related peptides (CRPs)9
together with “cathelicidin-related antimicrobial pep-
tides, CRAMPs”, which are also important for protec-
tion of skin infection.10 A role of at least some of
these AMPs in the composition of the mouse gut
flora as well as innate defence in the mouse gut is
well documented.11
ANTIMICROBIAL PEPTIDES IN HUMAN EPI-
THELIA
The findings that mammalian epithelia are capable to
defend infection by production of β-defensins sug-
gested that also human epithelial cells produce
AMPs. In the gut, epithelial granulocytes (“Paneth
cells”) represent a major source of antimicrobial pep-
tides, in particular the α-defensin HD-5,12 which is a
broad-spectrum antibiotic. Impaired HD-5 expression
in the gut, as seen in Crohn’s disease,13 has been dis-
cussed as cause of recurrent infections and inflamma-
tion in the gut. Although HD-5 is also present in the
genito-urinary tract, the antimicrobial peptide catheli-
cidin LL37 seems to represent its principle peptide
antibiotic protecting the urinary tract against invasive
bacterial infection.14
In the lung15 again epithelial LL37 seems to be of
relevance for innate defense, although a number of
other AMPs―including the β-defensin-1 (hBD-1)
seem to be relevant.16
INNATE ANTIBACTERIAL DEFENSE IN
HEALTHY SKIN
Healthy human skin is always covered with microor-
ganisms, but usually not infected by them. For long
time this per se unexpected observation was ex-
plained by the existence of a “physical defense
shield” consisting in the stratum corneum and a layer
of various lipids, together with an acidic pH.17 These
parameters are really very important for maintaining
an efficient protection, however is it sufficient?
Many microbes are known to optimally grow at
acidic conditions or on lipids! Thus one would expect
that human skin represents an optimal habitat for
such bacteria―which is indeed the case. However
why are these microbes unable to infect the skin un-
der healthy conditions, despite the fact that sufficient
nutrients seem to be there?
Because leukocytes are absent in healthy skin, the
only convincing explanation would be the existence
of an immune cell-independent keratinocyte-based
skin defense system.
Thus, one would expect strategies of the skin to
prevent infection without recruitment of inflamma-
tory cells. This would implicate the existence of a
“Chemical” or “Antimicrobial Defense Shield” of the
skin, where location-dependent different effector sys-
tems are activated.18 The skin surface would use a
strategy, which allows control of the microflora and
prevent infection by pathogens by limiting its growth
andor its colonization.
Recent analyses support this hypothesis: Based on
the observation that exposure of E. coli to the skin
surface killed it, the principal surface-located factor
was identified as psoriasin (S100A7).19 Psoriasin is a
preferentially E. coli killing AMP with a minimal in-
hibitory concentration (MIC) at low micromolar
doses by sequestrating Zn2+, as revealed by sensitiv-
ity of psoriasin E. coli-cidal activity towards pretreat-
ment with Zn2+.19 In vitro bactericidal concentrations
are easily achieved at various skin areas as revealed
by an in vivo-inhibition of bactericidal activity with a
neutralizing antibody.
Immunohistochemistry revealed a focal S100A7-
expression in the stratum granulosum and SC, the
epidermis of the upper parts of hair follicles with
strongest staining as well as in sebocytes and se-
bum.19
Washing experiments indicated that psoriasin is se-
creted in vivo in a topospecific manner.19 Highest lo-
cal amounts were detected in skin areas known to
show highest bacterial loads, e.g. on palma, planta,
axillae and the scalp.
In contrast to E. coli, the exposure of Staphylococ-
cus aureus to skin does not kill them.20 This is in ac-
cordance with the fact, that skin washing fluid has a
low S. a. killing capacity (unpublished results). In-
deed, S. a. killing activity is rather located within the
SC. As principal staphylocidal factor of SC-extracts
RNase-7 (R7) has been identified.21 R7 is a broad-
spectrum antimicrobial protein with strong activity at
low micromolar concentration against various gram-
positive and gramnegative bacteria as well as the
yeast Candida albicans. Of particular interest is the
unusual sensitivity of Enterococcus faecium and E. fae-
calis towards R7, which are killed at nanomolar con-
centrations.22
R7 is constitutively produced by keratinocytes and
can be induced further upon stimulation with inter-
feron γ.21
In contrast to skin washing fluid, SC-extracts re-
vealed strong staphylocidal activity, which could be
markedly blocked by neutralizing R7-antibodies, a
finding which supports an important role of R7 in
natural defense against S. a. skin infection.23 This is
further supported by ex vivo-experiments with skin
explants, where R7-antibody pretreatment of skin ex-
plants led to an increased S. a. growth.23
Thus, the stratum corneum itself may act, apart
from its physical barrier properties, as a second
“Chemical Defense Shield”, which contains several
antimicrobial peptides and proteins.
Using a biochemical approach in heel SC extracts
as second principal S. aureus killing AMP lysozyme
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has been identified.24 It should be noted that, unlike
in secretions such as saliva, tears or vaginal secre-
tions, skin washing fluid does not contain lysozyme,19
suggesting that lysozyme in healthy skin is rather a
component of the “second chemical barrier”, located
within the corneocytes. Interestingly, most S. a.
strains are resistant against lysozyme.25
The third staphylocidal AMP of potential relevance
in healthy skin and mucosa is calprotectin, a het-
erodimeric non-covalent complex of S100A8 and
S100A9: Calprotectin represents one of the principal
neutrophil proteins.26 It has been abundantly found in
vaginal secretions27 and was recently identified to be
focally expressed in different skin areas as well as
mucosal epithelial cells.28 Calprotectin is a Ca2+-
binding protein, which also can bind Zn2+ and Mn2+.
Whereas Zn2+-binding properties account for its
Candida-cidal activity,29 Mn2+-binding properties
cause S. aureus-killing properties.30 This is achieved
by depleting the S. a. Mn2+-superoxide dismutase
from its essential trace-element Mn2+, thus causing
suicidal killing of S. a. by oxygen radicals.30
Another AMP of potential relevance in healthy skin
is Dermcidin, which represents the principle sweat
antimicrobial peptide.31 Dermcidin is constitutively
produced exclusively by eccrine gland cells. It is ex-
pressed as a 9.3 kDa-precursor, which, after prote-
olytic cleavage, forms dermcidin 1 (DCD-1), a 47-aa-
peptide fragment with antimicrobial activity against S.
aureus and other bacteria and fungi at concentrations
in the range 1-10 μgml.32 Anionic as well as cationic
dermcidin-peptides reveal similar antimicrobial prop-
erties without showing visible membrane effects
upon ultrastructural analyses.33 It is therefore likely
that dermcidin has yet not known intracellular targets
in S. aureus.34
INNATE ANTIBACTERIAL DEFENSE IN IN-
FLAMED SKIN
Upon skin infection several AMPs are induced in
keratinocytes. The quantitatively most abundant in-
ducible AMP is human beta-defensin-2 (hBD-2).35 It
is absent in healthy skin, but found as one of the
quantitatively dominating peptides in lesional pso-
riatic skin.24 hBD-2 can be induced by proinflamma-
tory cytokines such as IL-1α, IL-1β, TNF-α35-37 as well
as IL-17 and IL-22.38-40
IL-17 and IL-22 seem to be the most powerful hBD-
2-inducers in primary keratinocyte cultures in vitro.41
hBD-2 is focally expressed in lesional keratinocytes
of the stratum granulosum e.g. in psoriasis lesions
and wounds42 or in infected skin areas.43 Papillo-
mavirus-infection also seems to induce hBD-2,44
which may point towards a yet unproven possible role
of hBD-2 as a papillomavirus-infection targeting fac-
tor.
hBD-2 is targeting gramnegative bacteria-such as
E. coli und Pseudomonas aeruginosa and to a lesser
extent also yeasts-such as Candida albicans.35,45 It is
almost inactive against S. aureus,46 suggesting that
this defensin might play a limited role as antibiotic in
epithelial defense responses against S. aureus.
hBD-2 can also be induced by bacterial pathogen-
associated molecular patterns, PAMPs:
Although several studies have shown that in epi-
thelial cells of the lung and the skin stimulation with
bacterial lipopolysaccharide (LPS)-preparations lead
to a transcriptional hBD-2-induction, concentrations
of the stimulus were in the range of 1-100 μgml, sug-
gesting that likely a trace contamination accounts for
the hBD-2-induction. Indeed, the use of chemically
synthesized LPS did not induce hBD-2 (our unpub-
lished results). TLR2-ligands have been controver-
sially discussed to be inducers of hBD-2. Whereas it
was shown that TLR2 and NALP2 mediate induction
of hBD-2 by Fusobacterium nucleatum in gingival epi-
thelial cells,47 in primary skin keratinocytes a syn-
thetic TLR2 ligand did not induce hBD-2.48
The as yet most potent and efficient inducer of
hBD-2 (transcription and protein production) is the
TLR5-ligand flagellin, which is active at picomolar
concentrations.49
Interestingly, flagellin is present as a soluble pro-
tein after shedding from Pseudomonas aeruginosa,
when these bacteria are colonizing and forming
biofilms, which occurs at starvation conditions.49 The
shedding is mediated by rhamnolipids, a special kind
of biosurfactants generated upon quorum sensing.50
hBD-2 is also efficiently induced in skin keratino-
cytes by the synthetic TLR3-ligand PolyI: C,48 which
may indicate that the natural TLR3-ligand double
stranded RNA represents an important hBD-2 in-
ducer. The observation that also TLR9 ligands induce
a moderate hBD-2-induction in keratinocytes let also
microbial DNA be able to activate the hBD-2-
production in keratinocytes.
Another important inducible epithelial AMP is
hBD-3.51 This AMP is mostly absent from healthy
skin, but it is strongly induced in psoriasis lesions,
upon wounding as well as in infection. hBD-3 is, un-
like hBD-2, a broad-spectrum peptide antibiotic.51,52 It
is active against S. aureus, various Gram-negative
bacteria as well as Candida albicans at low micromo-
lar concentrations. Ultrastructural analyses of hBD-3-
treated S. aureus reveal blebs and cell wall disruption,
similar as seen for Penicillin-treated S. a..51 Recent
studies have shown that hBD-3 inhibits cell wall bio-
synthesis in S. a. by interference with the lipid II bio-
synthesis,53 similar as seen for the fungal defensin
plectasin.54
Tissue studies of hBD-3 expression revealed tran-
scripts in epithelia of many organs and in some non-
epithelial tissues. As major sources of hBD-3 kerati-
nocytes of the skin and gingiva, trachea, esophagus,
tonsils, placenta, heart, skeletal muscle and fetal thy-
mus were identified.51,52
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High amounts of hBD-3 peptide are found in kerati-
nocytes of the wound edge55 and in lesional psoriatic
skin.51
Whereas IL-1 is one of the most powerful hBD-2-
inducers, IFNγ is the most potent and efficient hBD-3-
inducing cytokine.51 Although the direct contact of
epithelial cells with bacteria lead to hBD-3-induction
in vitro51 and in vivo, followed by bacterial killing,55
the mechanism needs to be elucidated, although
most likely it is mediated by an EGFR-ligand.56 The
most powerful hBD-3-inducers are EGFR-ligands
such as TGF-α and other, at the keratinocyte surface
located ligands of the EGFR. Therefore a trans-
activation process, which is mediated by metallo-
proteinase-dependent shedding of cell-bound EGFR-
ligands, seems to be the most relevant pathway of
hBD-3-induction in vivo.55
The cathelicidin LL37 is another inducible AMP. It
is produced as a precursor termed hCAP18, which is
cleaved by proteases to generate antimicrobially ac-
tive C-terminal fragments like LL37. Neutrophils rep-
resent the by far dominating cellular source of
hCAP18, where it is located in the secondary (“spe-
cific”) granules. Proteinase 3 cleaves hCAP18 gener-
ating the cathelin domain and the antimicrobial pep-
tide LL37.57 hCAP18 is expressed by many cells in-
cluding lung epithelial cells and skin keratinocytes.58
Keratinocytes express hCAP18LL37 at sites of in-
flammation.59 In skin, hCAP18 is processed by KLK5,
resulting in multiple C-terminal cleavage products.60
The in vivo concentration of keratinocyte-derived
LL37 in skin seems to be too low to exert direct an-
timicrobial effects. But several immunomodulatory
properties of LL37 have been identified, which indi-
cate that this peptide is rather acting as a host-
defense peptide than as an AMP.61 Indeed, LL37, af-
ter binding to DNA, acts as ligand for TLR9 and acti-
vates plasmacytoid dendritic cells for IFN-α produc-
tion.62
Mature LL37 peptide has been found in sweat,63 al-
though another study failed to detect it using SELDI-
TOF-MS.32
Mechanisms of hCAP18LL37-induction in skin are
not well understood. hCAP18LL37 immunoreactivity
is found in keratinocytes at the wound edge and after
treatment with Vitamin D3 [1,25(OH)2D3],59,64 as
seen in macrophages.65
It should be notified, however, that hCAP18LL37-
immunoreactivity was mainly seen in the basal kerati-
nocyte layer, unlike the defensins, RNase-7 and pso-
riasin, thus supporting the hypothesis that hCAP18
LL37 has a different function in skin innate defense.
ANTIMICROBIAL PEPTIDES AND ATOPIC
DERMATITIS
Patients with atopic dermatitis (AD) often suffer from
bacterial and viral infections of the skin.66,67 Among
bacterial infections S. aureus is the predominant
pathogen. Nearly 90% of AD patients have been
shown to be colonized with S. aureus, whereas only 5
to 30% were colonized in a control population.66
These observations forced the hypothesis that an
impaired epidermal AMP-expression in atopic skin
may contribute to an increased susceptibility towards
S. a.-infection.
Indeed, when the expression of hBD-2 and LL-37 in
the epidermis of AD patients and patients with psoria-
sis was compared, a markedly reduced expression of
both AMPs was seen.68 However with these findings
it was difficult to explain the increased S. a. infections
in AD patients, because hBD-2 is preferentially killing
Gram-negative bacteria and the role of keratinocyte-
derived LL-37 in defense of S. a.-infection is not clear.
With the hypothesis that possibly an epidermis-
derived, S. a.-killing AMP is of importance, the ex-
pression of hBD-3 has been investigated. By immuno-
histochemistry and realtime PCR epidermal expres-
sion of hBD-3 was seen to be much lower in AD,
when compared with psoriasis lesions.69 It was hy-
pothesized that Th2-cytokines like IL-4 and IL-13 may
cause this low expression, because both inhibited the
expression of hBD-2 and hBD-3 in keratinocyte cul-
tures.69 This observation is of particular importance
because hBD-3 has been identified as an important
keratinocyte-derived AMP that is able to control the
growth of S. aureus in a skin explant model.70
The role of hCAP18LL-37 in atopic skin remains
elusive. Recent studies have shown that healthy skin
and non-lesional atopic and psoriatic skin show very
low hCAP18LL-37 level.64 Although the previous
finding of decreased levels of hCAP18LL-37 mRNA
and hCAP18LL-37-immunoreactivity in lesional
atopic skin (compared with lesional psoriatic skin)68
was confirmed,64 there are marked differences in the
immunohistochemistry data: Whereas Ballardini et
al. found increased hCAP18LL-37-immunoreactivity
in epidermal cells close to injury as well as in dermal
infiltrate cells,71 Mallbris et al. reported about de-
creased immunostaining in keratinocytes close to in-
jury in atopic dermatitis.64 Reasons for these discrep-
ancies are yet not clear, but may originate from the
use of a monoclonal vs polyclonal hCAP18LL-37 anti-
body.
Nevertheless, there seem to be differences, when
the role of barrier disruption was studied: A very re-
cent study64 indicated that in AD lesions, in contrast
to healthy persons, the expression of hCAP18 mRNA
was markedly suppressed following wounding.
Investigations on the role of Dermcidin (DCD),
which is constitutively expressed in human eccrine
sweat glands and secreted into sweat, have shown
that patients with AD have a reduced amount of DCD
peptides in sweat.72 Moreover, the amount of several
DCD-derived peptides, which are at least in part po-
tent staphylocidal peptides, in sweat of patients with
AD were found to be reduced. Interestingly, in AD
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patients with a history of bacterial and viral skin infec-
tions less DCD-1 peptides were found in their sweat.
In healthy subjects, sweating was observed to lead to
a reduction of viable bacteria on the skin surface, but
this was not seen in patients with AD. Thus, DCD
peptides in sweat of patients with AD may contribute
to the high susceptibility of these patients to skin in-
fections and altered skin colonization,72 although its
role in S. aureus colonization of healthy skin remains
to be determined.
In a recent systematic analysis, putatively relevant
AMPs (constitutively produced RNase 7 and pso-
riasin, and the inducible AMPs, hBD-2 and hBD-3)
were determined in healthy, psoriatic, and chronic as
well as acute atopic skin. Tissues samples and skin
washing fluids derived from healthy and SCORAD-
and S. aureus colonization-matched AD-patients were
analyzed for the expression and the in vivo secretion
of these AMPs. As a result the authors have shown
that all four AMPs are induced in both non-lesional
and lesional skin of psoriatic and atopic patients when
compared with the skin of healthy individuals.73
It was further found that superficial barrier disrup-
tion by tape stripping, which caused in healthy skin
an increased production and release of psoriasin,41
also induced the expression of hBD-2, hBD-3, and
RNase 7. Thus the enhanced expression of AMPs in
psoriatic and AD skin may be driven―at least in part-
by a disrupted epidermal barrier.
The absolute levels of AMP expression and secre-
tion were found to be lower than levels detected in
psoriasis, which is in agreement with published re-
sults,68,69,74 but in this study neither a correlation be-
tween the secretion of AMPs (RNase 7, psoriasin,
hBD-2, and hBD-3) and S. aureus colonization nor a
correlation between AMP secretion and SCORAD
was found.73 These findings may be interpreted that
reduced amounts of the analyzed AMPs, in particular
the most abundant staphylocidal AMPs of healthy
skin, do not cause the increased susceptibility of AD
skin to S. aureus colonization and infection.
ATOPIC DERMATITIS AND REGULATION
OF EPITHELIAL ANTIMICROBIAL PEPTIDE
PRODUCTION
Several previous studies reported about decreased
tissue expression of various skin-AMPs in AD-
patients, when compared with patients with psoriasis,
which suggest that induction and regulation of
keratinocyte-derived AMP production and release is
altered in AD, relative to psoriasis. A recent study,
however, revealed no significant differences in the
differences of the expression-levels in lesional skin vs
non-lesional skin of the AMPs cathelicidin, hBD-2
and hBD-3 in AD, relative to psoriasis.75 However, a
history of eczema herpeticum is associated with the
inability to induce these AMPs in the skin of AD pa-
tients.75
A critical inducer of AMPs upon infection is IL-17A,
which often acts synergistically with IL-22.76 These
cytokines represent the most powerful inducers of
keratinocyte-derived AMPs such as hBD-2, S100-A7,
S100A8A9. On the other side, IL-17 has been shown
to be essential for host defense against many mi-
crobes, particularly extracellular bacteria and fungi.77
This is further supported in the autosomal domi-
nant hyper-IgE syndrome (HIES, ‘Job’s syndrome’),
which is characterized by recurrent and often severe
pulmonary infections, eczema, staphylococcal ab-
scesses and mucocutaneous candidiasis. Here muta-
tions presumed to underlie HIES have recently been
identified in the gene encoding STAT3 (signal trans-
ducer and activator of transcription 3).78 STAT3 sig-
nalling is essential for the generation of Th17 cells
and the inability to produce Th17 cells is a mecha-
nism underlying the susceptibility to the recurrent in-
fections commonly seen in HIES.79 Further, the find-
ing that IL-17A (--) mice show an increased suscepti-
bility to infection by S. aureus,80 a direct relationship
seems to be intriguing.
Therefore a lack of major AMP inducers such as
IL-17 in AD skin, and suppression of AMP induction
by elevated levels of Th2 cytokines, demonstrated in
vitro for IL-4, IL-10, and IL-13, would explain the
lower AMP levels in AD when compared with psoria-
sis.69,74 Interestingly, a recent study revealed that in
patients with acute exacerbation of AD, secretion
level of hBD-2 and RNase 7 were higher when com-
pared with patients with chronic AD.81 In addition,
hBD-3 has been detected in the lesional skin of 80% of
the patients characterized by acute exacerbation of
AD. Increased Th2 cytokine level, which have been
associated with acute AD, appear not to be sufficient
enough to inhibit the induction of AMPs, such as
hBD-2, hBD-3 and RNase 7, in the acute AD lesion.
The data of this study further indicate that the in-
duction of AMPs is not generally impaired in the skin
of patients suffering from AD.
Nevertheless, the role of Th17 cells and IL-17A in
AD is still elusive: In contrast to what has been ex-
pected, increased IL-17+ T cells have been identified
in tissue sections of acute AD lesions relative to nor-
mal skin.82 Another study also demonstrated in-
creased IL-17 expression in chronic AD lesions, when
compared with normal skin, but the overall expres-
sion of the IL-23TH17 pathway is much reduced
compared with psoriasis.83
Among the known principal staphylocidal
keratinocyte-derived AMPs, only S100A8A9 is in-
duced by IL-17IL-22.84 There is yet no experimental
evidence that hBD-3 (which is induced in these cells
by IFN-γ and EGFR-ligands) and RNase-7 (which is
constitutively expressed and further induced by yet
unknown mechanisms upon inflammation) are in-
duced by IL-17.
More strikingly, there has been found a strong cor-
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relation between RNase 7 transcript number, but not
for hBD-2 or hBD-3, in healthy skin and the propen-
sity of healthy individuals to develop S. aureus-
positive skin infections.85 This is in accordance with
the finding that R7 protein is the most relevant
staphylocidal AMP in SC-extracts.23 Therefore R7
could represent a candidate AMP in AD-associated S.
aureus infection. Although in a recent study no de-
creased RNase-7 amounts were detected in AD-skin-
washing fluids, the concentrations were far below
bactericidal concentrations.73 It is possible that
amounts of SC-bound R7 differ between AD-patients
and healthy persons.
CONCLUSION AND OUTLOOK
Although there is lots of evidence that keratinocyte-
derived AMPs have an important role in controlling
microbial growth and inhibiting infection at the sur-
face of healthy skin, it is still not clear, why recurrent
S. aureus skin infections occur in AD. An important
factor promoting skin infection in AD is a disturbed
skin barrier. The barrier defect leads to an increased
number of wounds, which would expect a massive in-
duction of various keratinocyte-derived AMPs in the
wound margin. But this seems―unlike in psoriasis―
not to be the case. All yet available experimental data
point towards a role of keratinocyte-derived AMPs
rather at a quantitative than qualitative level.
It is currently not clear whether we are missing
key components controlling S. aureus infection at the
AD skin surface: One important and yet not well ad-
dressed parameter could be the role of the commen-
sal microflora in controlling skin-infection. Microbes
can produce AMPs (so-called microcins),86 which are
more or less target-microbe-specific. So, if the micro-
biom on AD skin is altered, this would have effects on
colonization of S. aureus―as seen in healthy per-
sons.87 Further, the commensal microflora―as all
bacteria―is able to produce low molecular antibiot-
ics, which have neither studied at the skin surface
nor in detail in all components of the human skin mi-
crobiom.
Future studies will address key questions on the
role of low MW antibiotics, which have been secreted
in situ by the residential microflora―together with
surface-located host epithelia-derived AMPs and its
precursors.
Studying these complex processes will enable us to
better understand the initial phases of bacterial skin
infection in AD and especially to get a convincing ex-
planation, why especially S. aureus causes skin infec-
tion in AD.
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